Axogen, Inc. (AXGN) · Oct 28, 2026 · Earnings
Beat — Adjusted EPS $0.21 vs ~$0.13 consensus; revenue $75.8M vs ~$73.2M
Axogen’s Q3 earnings beat consensus on revenue and adjusted EPS, while management raised 2026 revenue guidance and advanced prostate expansion.
Axogen is expanding a peripheral-nerve-repair business beyond its established extremities and head-and-neck markets, using Avance coverage gains, larger commercial teams, breast reconstruction adoption, and a developing prostate opportunity to pursue faster growth. The prior quarter had already established that revenue growth and the broader commercial expansion were working, while full-year revenue guidance stood at at least 24% growth or $279 million.
The quarter clearly beat the market’s operating expectations. Revenue reached $75.8 million, up 26.2% year over year, versus published consensus of roughly $73.2 million; adjusted diluted EPS was $0.21 versus roughly $0.13 expected. That is a meaningful beat on both top line and earnings, not merely a revenue outperformance with weaker conversion. Q3 revenue was $75.8M, +26.2% YoY.
| Metric | Q3 2026 | Q3 2025 | Comparison / expectation |
|---|---|---|---|
| Revenue | $75.8M | $60.1M | +26.2%; vs ~$73.2M consensus |
| Adjusted diluted EPS | $0.21 | $0.12 | vs ~$0.13 consensus |
| Adjusted EBITDA | $13.4M | $9.2M | +45%; margin 17.7% vs 15.4% |
| GAAP diluted EPS | $0.04 | $0.01 | Positive GAAP earnings |
| Free cash flow | $18.9M | $(5.9)M | Improved materially |
| Gross margin | 74.8% | 76.6% | Down 1.8 percentage points |
The bigger change is the guidance raise, not just the quarterly beat. Axogen moved full-year revenue growth to at least 29%, or $290 million, from the prior 24%/$279 million target, and added an organic-growth target of at least 26%, or $283 million. That materially raises the bar for the business and indicates the stronger demand and commercial execution are being carried into Q4 rather than treated as a one-quarter spike. The filing states: “Revenue growth of at least 29% or $290million; Organic revenue growth of at least 26% or $283million.”
Profitability is improving, although the margin story is not uniformly clean. Adjusted EBITDA margin rose to 17.7% from 15.4%, and free cash flow turned strongly positive year to date, but gross margin fell to 74.8% from 76.6%, reflecting mix pressure associated with faster breast growth. The company is therefore growing faster and converting more of that growth into adjusted earnings, while product mix still limits gross-margin expansion. Q3 Adjusted EBITDA* was $13.4M, +2.3 pp as a percent of revenue YoY.
The strategic story also advanced, but the next leg remains prostate-dependent. Breast revenue grew more than 50% year over year, Avance commercial coverage reached approximately 96% of covered U.S. lives, and BioCircuit’s NerveTape adds a complementary coaptation product. Those developments strengthen the company’s expansion platform, but prostate remains an opportunity rather than established revenue: Axogen cites 220-plus procedures and 15 clinical experience sites, with detailed outcomes due November 9. The filing says: “Detailed clinical outcomes to be reported November 9, 2026.” 〔0〕
Bottom line: This is a genuinely stronger-than-expected quarter with a meaningful revenue-guidance raise, confirming that Axogen’s commercial expansion is translating into faster growth and better adjusted profitability. The key unresolved question is whether the upcoming prostate data can support the next phase of that growth story.
Prostate clinical outcomes webcast, November 9, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!